Advertisement

Early Treatment of the Common Cold with Intranasal Interferon Alpha-2a (Ro 22–8181): A Preliminary Pilot Study

  • R. Berger
  • M. Just
  • O. Ruuskanen
  • M. Lüdin
  • S. N. Linder-Ciccolunghi
Chapter
  • 43 Downloads

Abstract

It is well established that intranasal IFN Alpha-2a is effective in preventing experimental and natural rhinovirus-induced common cold (1–3). Seven-day contact prophylaxis is well tolerated and approximately 80% of rhinovirus respiratory virus infections are prevented (4, 5). There is little information about therapeutic effect of intranasal interferon in symptomatic patients. Hayden and Gwaltney (6) found only modest effects on nasal symptoms in experimentally induced rhinovirus infection when treatment was initiated 28 hours after the virus inoculation.

Keywords

Respiratory Syncytial Virus Acute Respiratory Tract Infection Respiratory Syncytial Virus Infection Common Cold Total Symptom Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Scott CM, Phillpotts RJ, Wallace J, Gauci CL, Creiner J and Tyrrell DAJ: Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet 1982; i: 186–189.CrossRefGoogle Scholar
  2. 2.
    Herzog C, Berger R, Fernex M, Friesecke K, Haval L, Just M, Dubach UC, Havas L, Just M and Dubach U: Intranasal interferon (rIFN-alpha A, Ro 22–8181) for contact prophylaxis against common cold: a randomized, double-blind and placebo-controlled field study. Antiviral Research 1986; 6: 171–176.PubMedCrossRefGoogle Scholar
  3. 3.
    Intranasal interferon alpha-2 prophylaxis of natural respiratory virus infection. The Journal of Infectious Diseases 1985; 151, No. 46.Google Scholar
  4. 4.
    Douglas RM, Moore BW, Miles HB, Davies LM, Neil RN, Graham MH, Ryan P, Worswick DA and Albrecht JK: Prophylactic efficacy of intranasal alpha-2-interferon against rhinovirus infections in the family setting. New England Journal of Medicine 1986; 314, No. 2: 65–70.CrossRefGoogle Scholar
  5. 5.
    Hayden FR, Albrecht JK, Kaiser DL and Gwaltney JM: Prevention of natural colds by contact prophylaxis with intranasal alpha-2-interferon. New England Journal of Medicine 1986; 314, No. 2: 71–75.CrossRefGoogle Scholar
  6. 6.
    Hayden FG and Gwaltney JM: Intranasal interferon alpha-2 treatment of experimental rhinoviral colds. The Journal of Infectious Diseases 1984; 150, No. 2: 174–180.CrossRefGoogle Scholar
  7. 7.
    Hennes U, Jucker W, Fischer EA, Krummenacher T, Palleroni AV, Trown PW, Linder-Ciccolunghi S and Rainisio M: Detection of antibodies to recombinant interferon alpha 2a in human serum: Evaluation of three methods. Submitted to J. of Biological Standardization.Google Scholar
  8. 8.
    Halonen P and Meurman O (1982): Radioimmunoassay in diagnostic virology. In: New developments in practical virology. Ed. Howard CR (Alan R. Liss, New York ), pp 83–124.Google Scholar
  9. 9.
    Monto AS, Shope TC, Schwartz SA and Albrecht JK: Intranasal interferon alpha-2b for seasonal prophylaxis of respiratory infection. The Journal of Infectious Diseases 1986; 154, No. 1: 128–133.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Dordrecht 1987

Authors and Affiliations

  • R. Berger
    • 1
  • M. Just
    • 1
  • O. Ruuskanen
    • 2
  • M. Lüdin
    • 1
  • S. N. Linder-Ciccolunghi
    • 2
  1. 1.University Children’s HospitalBasleSwitzerland
  2. 2.Clinical Research DepartmentF. Hoffmann-La Roche and Co. Ltd.Switzerland

Personalised recommendations